Skip to content
10-Q

Quarterly Report

Taysha Gene Therapies, Inc. TSHA

0001193125-25-263506

← back to feed
Filed
Nov 4, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 4, 2025 273.92M sh
Shares Diluted Q3 2025 · Sep 30, 2025 353.31M sh
Shares Diluted Q3 2025 · Sep 30, 2025 307.18M sh
Shares Diluted Q3 2025 · Sep 30, 2024 267.82M sh
Shares Diluted Q3 2025 · Sep 30, 2024 244.05M sh
Capex Q3 2025 · Sep 30, 2025 $488K
Capex Q3 2025 · Sep 30, 2024 $376K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$66.37M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$62.92M
Long Term Debt Q3 2025 · Sep 30, 2025 $50.85M
Long Term Debt Q3 2025 · Dec 31, 2024 $43.94M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $297.34M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $139.04M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $157.69M
Stockholders Equity Q3 2025 · Sep 30, 2025 $218.99M
Stockholders Equity Q3 2025 · Jun 30, 2025 $248.73M
Stockholders Equity Q3 2025 · Dec 31, 2024 $71.53M
Stockholders Equity Q3 2025 · Sep 30, 2024 $88.8M
Stockholders Equity Q3 2025 · Jun 30, 2024 $108.87M
Stockholders Equity Q3 2025 · Dec 31, 2023 $74.94M
Current Liabilities Q3 2025 · Sep 30, 2025 $28.63M
Current Liabilities Q3 2025 · Dec 31, 2024 $26.23M
Total Liabilities Q3 2025 · Sep 30, 2025 $97.57M
Total Liabilities Q3 2025 · Dec 31, 2024 $88.84M
Current Assets Q3 2025 · Sep 30, 2025 $299.95M
Current Assets Q3 2025 · Dec 31, 2024 $142.13M
Total Assets Q3 2025 · Sep 30, 2025 $316.55M
Total Assets Q3 2025 · Dec 31, 2024 $160.36M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.09
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.26
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.10
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.29
Eps Basic Q3 2025 · Sep 30, 2025 −$0.09
Eps Basic Q3 2025 · Sep 30, 2025 −$0.26
Eps Basic Q3 2025 · Sep 30, 2024 −$0.10
Eps Basic Q3 2025 · Sep 30, 2024 −$0.29
Sga Expense Q3 2025 · Sep 30, 2025 $8.28M
Sga Expense Q3 2025 · Sep 30, 2025 $25.04M
Sga Expense Q3 2025 · Sep 30, 2024 $7.9M
Sga Expense Q3 2025 · Sep 30, 2024 $22.32M
Rd Expense Q3 2025 · Sep 30, 2025 $25.75M
Rd Expense Q3 2025 · Sep 30, 2025 $61.45M
Rd Expense Q3 2025 · Sep 30, 2024 $14.95M
Rd Expense Q3 2025 · Sep 30, 2024 $50.68M
Net Income Q3 2025 · Sep 30, 2025 −$32.73M
Net Income Q3 2025 · Sep 30, 2025 −$81.14M
Net Income Q3 2025 · Sep 30, 2024 −$25.52M
Net Income Q3 2025 · Sep 30, 2024 −$70.51M
Operating Income Q3 2025 · Sep 30, 2025 −$34.02M
Operating Income Q3 2025 · Sep 30, 2025 −$82.2M
Operating Income Q3 2025 · Sep 30, 2024 −$25.9M
Operating Income Q3 2025 · Sep 30, 2024 −$71.53M
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2025 $4.29M
Revenue Q3 2025 · Sep 30, 2024 $1.79M
Revenue Q3 2025 · Sep 30, 2024 $6.31M